摘要
目的比较利奈唑胺与万古霉素治疗老年人医院获得性耐甲氧西林金黄色葡萄球菌（MRSA）肺炎的疗效和安全性。方法57例老年医院获得性MRSA肺炎患者随机分成利奈唑胺组（29例）与万古霉素组（28例），疗程结束后比较两组临床有效率、细菌学清除率及不良反应情况。结果利奈唑胺组临床有效率75．9％，万古霉素组67．9％，两组差异无统计学意义（P〉0．05）。利奈唑胺组血小板减少发生率20．7％，用药前后的差异有统计学意义（P〈0．05）；万古霉素组肾功能损害发生率14．2％。结论利奈唑胺治疗老年人医院获得性肺炎临床疗效与万古霉素相仿，但其不良反应相对轻微。
Objective To compare the effectiveness and safety of linezolid and vancomycin in the treatment of elderly patients with hospital acquired pneumonia （HAP） caused by methicillin-resistant Staphylococcus aureu （MRSA）. Methods A total of 57 elderly patients with HAP caused by MRSA were randomly divided into a linezolid group （n=29） and a vancomycin group （n=28）. After treatment, both groups were compared for effectiveness, bacterial clearance rate and side effects. Results The total effective rate was 75.9 % for the linezolid group and 64,7% for the vancomycin group, without significant differences between them （P 〉 0.05）. The incidence of thrombocytopenia induced by linezolid was 20.7%, which was remarkably different from the pre-treatment level （P〈0.05）. The rate of acute kidney injury induced by vancomycin was 14.2 %. Conclusion Linezolid has similar effectiveness with vancomycin during the treatment of elderly patients with HAP caused by MRSA, with slight adverse reactions.
出处
《中国急救复苏与灾害医学杂志》
2015年第6期567-570,共4页
China Journal of Emergency Resuscitation and Disaster Medicine
基金
解放军305医院青年科研基金（11YB2）
